The APOE Genotype: Modification of Therapeutic Responses in Alzheimer's Disease

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|21|1|114-120

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.21, Iss.1, 2015-01, pp. : 114-120

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

ApoE genotype influences the biological effect of donepezil on APP metabolism in Alzheimer disease: evidence from a peripheral model

By Borroni B.   Colciaghi F.   Pastorino L.   Archetti S.   Corsini P.   Cattabeni F.   Di Luca M.   Padovani A.  

European Neuropsychopharmacology, Vol. 12, Iss. 3, 2002-06 ,pp. : 195-200

Elsevier

Access to resources Recommend Favorite

Apolipoprotein E4 (ApoE4) genotype and/or gender do not appear to predict a response to donepezil in patients with mild-to-moderate Alzheimer's disease

By  

Inpharma, Vol. 1, Iss. 1248, 2000-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Cholesterol and Apoe: A Target for Alzheimer's Disease Therapeutics

By  

Current Drug Targets-CNS & Neurological Disorders, Vol. 4, Iss. 5, 2005-10 ,pp. : 553-567

Bentham Science Publishers

Access to resources Recommend Favorite

Therapeutic Agents for Alzheimer's Disease

By  

Current Medicinal Chemistry - Central Nervous System Agents, Vol. 5, Iss. 4, 2005-01 ,pp. : 259-269

Bentham Science Publishers

Access to resources Recommend Favorite

Therapeutic Potential in Alzheimer Disease

By  

Current Medicinal Chemistry, Vol. 9, Iss. 17, 2002-09 ,pp. : 1605-1610

Bentham Science Publishers

Access to resources Recommend Favorite